Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Status:
Active, not recruiting
Trial end date:
2022-11-04
Target enrollment:
Participant gender:
Summary
The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the
addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients
with advanced EGFR-mutant NSCLC.